Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Inhibition of α-synuclein aggregation and mature fibril disassembling with a minimalistic compound, ZPDm

  • Peña Díaz, Samuel|||0000-0002-2902-823X
  • Pujols Pujol, Jordi|||0000-0001-9424-5866
  • Garcia de Carvalho Pinheiro, Francisca|||0000-0003-3778-1528
  • Santos Suárez, Jaime|||0000-0001-9045-7765
  • Pallarès i Goitiz, Irantzu|||0000-0002-8205-2060
  • Navarro, Susanna|||0000-0001-8160-9536
  • Conde Giménez, María|||0000-0003-4358-9110
  • García, Jesús
  • Salvatella, Xavier|||0000-0002-8371-4185
  • Dalfo, Esther|||0000-0003-4677-8515
  • Sancho Sanz, Javier|||0000-0002-2879-9200
  • Ventura, Salvador|||0000-0002-9652-6351
Synucleinopathies are a group of disorders characterized by the accumulation of α-Synuclein amyloid inclusions in the brain. Preventing α-Synuclein aggregation is challenging because of the disordered nature of the protein and the stochastic nature of fibrillogenesis, but, at the same time, it is a promising approach for therapeutic intervention in these pathologies. A high-throughput screening initiative allowed us to discover ZPDm, the smallest active molecule in a library of more than 14.000 compounds. Although the ZPDm structure is highly related to that of the previously described ZPD-2 aggregation inhibitor, we show here that their mechanisms of action are entirely different. ZPDm inhibits the aggregation of wild-type, A30P, and H50Q α-Synuclein variants in vitro and interferes with α-Synuclein seeded aggregation in protein misfolding cyclic amplification assays. However, ZPDm distinctive feature is its strong potency to dismantle preformed α-Synuclein amyloid fibrils. Studies in a Caenorhabditis elegans model of Parkinson's Disease, prove that these in vitro properties are translated into a significant reduction in the accumulation of α-Synuclein inclusions in ZPDm treated animals. Together with previous data, the present work illustrates how different chemical groups on top of a common molecular scaffold can result in divergent but complementary anti-amyloid activities.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Caenorhabditis elegans RAC1/ced-10 mutants as a new animal model to study very early stages of Parkinson's disease

  • Muñoz Juan, Amanda|||0000-0001-9549-782X
  • Benseny Cases, Núria|||0000-0003-4603-6829
  • Guha, Sanjib
  • Barba, Ignasi|||0000-0001-9886-3776
  • Caldwell, K A.
  • Caldwell, G A.
  • Agulló, Laura|||0000-0002-8739-0456
  • Yuste, Victor José|||0000-0001-5322-9261
  • Laromaine, Anna|||0000-0002-4764-0780
  • Dalfo, Esther|||0000-0003-4677-8515
Patients with Parkinson's disease (PD) display non-motor symptoms arising prior to the appearance of motor signs and before a clear diagnosis. Motor and non-motor symptoms correlate with progressive deposition of the protein alpha-synuclein (Asyn) both within and outside of the central nervous system, and its accumulation parallels neurodegeneration. The genome of Caenorhabditis elegans does not encode a homolog of Asyn, thus rendering this nematode an invaluable system with which to investigate PD-related mechanisms in the absence of interference from endogenous Asyn aggregation. CED-10 is the nematode homolog of human RAC1, a small GTPase needed to maintain the function and survival of dopaminergic neurons against human Asyn-induced toxicity in C. elegans. Here, we introduce C. elegans RAC1/ced-10 mutants as a predictive tool to investigate early PD symptoms before neurodegeneration occurs. Deep phenotyping of these animals reveals that, early in development, they displayed altered defecation cycles, GABAergic abnormalities and an increased oxidation index. Moreover, they exhibited altered lipid metabolism evidenced by the accumulation of lipid droplets. Lipidomic fingerprinting indicates that phosphatidylcholine and sphingomyelin, but not phosphatidylethanolamine or phosphatidylserine, were elevated in RAC1/ced-10 mutant nematodes. These collective characteristics reflect the non-motor dysfunction, GABAergic neurotransmission defects, upregulation of stress response mechanisms, and metabolic changes associated with early-onset PD. Thus, we put forward an easy-to-manipulate preclinical animal model to deepen our understanding of early-stage PD and accelerate the translational path for therapeutic target discovery.